Background: Cold-inducible RNA-binding protein is a novel damage-associated molecular pattern that causes inflammation. C23, a short peptide derived from cold-inducible RNA-binding protein, has been found to have efficacy in blocking cold-inducible RNA-binding protein's activity. We hypothesized that C23 reduces inflammation and tissue injury induced by intestinal ischemia-reperfusion. Methods: Male C57BL/6 mice were subjected to 60 minutes of intestinal ischemia by clamping the superior mesenteric artery. Immediately after reperfusion, either normal saline (vehicle) or C23 peptide (8 mg/kg body weight) was injected intraperitoneally. Four hours after reperfusion, blood, intestinal, and lung tissues were collected for analysis of inflammatory and tissue injury parameters. Results: Cold-inducible RNA-binding protein levels in the intestinal tissues were significantly increased following intestinal ischemia-reperfusion. Histologic examination of the intestine revealed a significant reduction in injury score in the C23 group by 48% as compared with the vehicles after intestinal ischemiareperfusion. The serum levels of lactate dehydrogenase and aspartate aminotransferase were increased in animals that underwent vehicle-treated intestinal ischemia-reperfusion, whereas C23-treated animals exhibited significant reductions by 48% and 53%, respectively. The serum and intestinal tissue levels of tumor necrosis factor α were elevated in vehicle-treated intestinal ischemia-reperfusion mice but decreased by 72% and 69%, respectively, in C23-treated mice. Interleukin-6 mRNA levels in the lungs were reduced by 86% in the C23-treated group in comparison to the vehicle-treated group after intestinal ischemiareperfusion. Expression of macrophage inflammatory protein 2 and level of myeloperoxidase activity in the lungs were dramatically increased after intestinal ischemia-reperfusion and significantly reduced by 91% and 25%, respectively, in the C23-treated group. Conclusion: C23 has potential to be developed into a possible therapy for reperfusion injury after mesenteric ischemia and reperfusion.
Introduction
Intestinal ischemia-reperfusion injury (I/R) is an inflammatory condition caused by the restoration of blood flow to previously ischemic bowel. This condition is seen in a myriad of clinical scenarios including acute thromboembolic mesenteric ischemia, molecules that are normally located intracellularly but, when released from the cell, serve as an alarm to the body's immune system that injury has occurred. 5, 6 DAMPs bind to Toll-like receptors (TLRs), which in turn activate the transcription factor nuclear factor-κB (NF-kB) that potentiates the production of cytokines and chemokines to further activate and recruit innate immune cells, such as macrophages and neutrophils. 7, 8 These innate immune cells infiltrate the reperfused tissue and produce further inflammation, ultimately inflicting more cellular injury than the original ischemic insult, primarily by disrupting local microcirculation. 9 The inflammatory response during the reperfusion phase is not only damaging to the original ischemic tissue but can also potentiate activation of inappropriate inflammation in remote organs, particularly in the lungs. 10 Multiple organ failure, particularly acute lung injury (ALI), is a common complication of intestinal I/R that contributes to the high mortality rate in intestinal I/R. 11, 12 ALI is caused by a systemic inflammatory response resulting from the release of proinflammatory cytokines and bacterial endotoxins from reperfused ischemic intestine. 13 Therefore, the development of therapies targeting the host response to DAMPs during intestinal I/R has clinical value in the treatment or prevention of both local and remote organ injury.
We have identified a new DAMP named cold-inducible RNAbinding protein (CIRP). 14 It is expressed constitutively at low levels in various tissues and normally functions as an RNA chaperone protein during translation. 15 During the hypoxic conditions of shock states, macrophages release CIRP, which induces the expression of proinflammatory cytokines, such as tumor necrosis factor α (TNF-α) and interleukin-6 (IL-6), proteins that significantly contribute to an inappropriate and damaging immune response. 14 In both animal and human models, CIRP has been reported to play a deleterious role in various critical care scenarios, such as hemorrhagic shock, sepsis, and kidney I/R. [16] [17] [18] [19] CIRP acts as a DAMP through its binding to TLR4 and myeloid differentiation factor 2 (MD2) complexes, which in turn potentiates the expression of proinflammatory cytokines. 14 We previously reported that CIRP knockout (CIRP -/-) mice undergoing intestinal I/R exhibited reduced local, systemic, and remote organ inflammation and injuries when compared with their wild-type (WT) counterparts. 20 With this confirmation of CIRP's damaging role in intestinal I/R, we aimed to block CIRP's effects in a way that could be translated into a human therapy. Many short sequences within the 172-amino-acid CIRP protein were screened for their binding affinity to TLR4-MD2 complex using surface plasmon resonance. A 15-mer peptide with the highest binding affinity for TLR4-MD2 complex was identified and named C23. 14 In previous work, our laboratory has demonstrated the efficacy of the CIRP-derived peptide, C23, in downregulating recombinant murine CIRP-induced TNF-α production by human macrophages in vitro. 21 In this study, we investigated C23's ability to mitigate inflammation and injury both locally and remotely in the lungs of mice undergoing intestinal I/R.
Methods

Animal model of intestinal I/R
Male C57BL/6 WT mice (7-9 weeks old, 20-25 g body weight) purchased from Charles River (Kingston, NY) were housed in temperature-controlled environments and fed a standard laboratory mouse diet. The animal model for intestinal I/R began with anesthetic induction with 2.5% inhalational isoflurane, followed by preparation of the abdomen with 10% povidone-iodine wash. Mouse anesthesia was maintained with 2% isoflurane inhalation. An upper midline laparotomy was performed to expose the abdomen, and the superior mesenteric artery was isolated. The superior mesenteric artery was then occluded with a vascular clip. On completion of 60 minutes of ischemia, the vascular clip was removed to allow reperfusion. After closure, all mice were resuscitated with 1 mL of normal saline administered subcutaneously. At the time of reperfusion, mice designated randomly to the treatment group received 8 mg of C23 per kilogram of body weight of the mouse through intraperitoneal injection in 200 μL of total volume adjusted with normal saline. We injected mice with normal saline intraperitoneally at 200 μL of total volume to serve as the vehicle control group. We euthanized the mice 4 hours after the intraperitoneal injection of C23 for the treatment group and normal saline for the vehicle group. Sham mice were not operated on and underwent organ and blood harvest while under anesthesia. The sample size for each experimental group was 5 mice. All experiments were performed in accordance with the guidelines for the use of experimental animals by the National Institutes of Health (Bethesda, MD) and were approved by the Institutional Animal Care and Use Committee of The Feinstein Institute for Medical Research.
Histologic analysis
Samples of small intestine non-necrotic areas of the distal ileum selected based on the color of the small intestine segment were fixed in 10% formalin and embedded in paraffin. The terminal ileum was chosen to ensure uniformity in segment selection among animals and prevent observer bias. In our previous studies on intestinal I/R injury model in mice we studied terminal ileum to investigate inflammation and injury. Tissue blocks were sectioned at a thickness of 5 mm, transferred to glass slides, and stained with hematoxylin and eosin. Morphologic examinations were performed in a blinded fashion using light microscopy, and intestinal I/R injury severity was scored using an established injury scoring system developed by Stallion et al. 22 The injury severity scale ranged from 0 to 4. In the scoring method, 0 represents a normal villus to crypt ratio, minimal number of lymphocytes and presence of tall columnar surface epithelial cells; 1 represents epithelial cell degenerative changes (cuboidal, vacuolated) and a mild increase in lymphocytes in lamina propria; 2 represents decreased villus height, epithelial cell necrosis, erosions, infiltration of neutrophils, and glandular dilatation; 3 represents affected villi (flat surface), epithelial cell necrosis, erosions, pseudomembrane on surface, glandular destruction, and inflammation extending deep to muscle layer; and 4 represents transmural changes together with all of the aforementioned parameters and change in muscle layer. 22 
Enzyme-linked immunosorbent assay
Intestinal tissue was homogenized in a lysis buffer (10 mM Tris-HCl, pH 7.5, 120 mM NaCl, 1% sodium deoxycholate, and 0.1 % sodium dodecyl sulfate) containing a protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN). Protein concentration was determined with the BioRad protein assay reagent (Hercules, CA).
TNF-α levels in the serum and intestinal tissue were determined with a mouse enzyme-linked immunosorbent assay (ELISA) kit (BD Biosciences, San Diego, CA). CIRP level in the serum were determined using the ELISA kit provided by LifeSpan Biosciences, Inc (Seattle, WA).
Ly6G/C staining of intestinal tissue
Intestinal tissue samples were de-waxed, incubated with proteinase K, stained using a green fluorescent-tagged Ly6G/C Ab, counterstained with propidium iodide, and examined under a fluorescence microscope. Ly6G/C cells appeared green fluorescent on a red background staining and were blindly counted per visual field at a 200 × magnification.
Analysis of serum injury markers
Blood samples were drawn prior to euthanasia from the inferior vena cava and centrifuged at 8,0 0 0 g for 10 minutes. The supernatant containing the serum was collected and then analyzed immediately for lactate dehydrogenase (LDH) and aspartate aminotransferase (AST) to serve as tissue injury markers. LDH and AST levels were measured in serum using assay kits from Pointe Scientific (Canton, MI) by following the protocol provided in the kits' literature, and the kinetic values were analyzed using a spectrophotometer (Synergy H1 Hybrid Reader, BioTek, South San Francisco, CA) at 340-nm wavelength.
Quantitative real-time polymerase chain reaction for determining expression of IL-6 and MIP-2 mRNAs in lung
Total RNA was extracted from lung tissue using a Trizol reagent (Invitrogen, Carlsbad, CA) and was reverse-transcribed into cDNA using reverse transcriptase enzyme (Applied Biosystems, Foster City, CA). A quantitative real-time polymerase chain reaction polymerase chain reaction (PCR) assay was carried-out in 20 μL of a final volume containing 0.08 μmol of each forward and reverse primer, cDNA (2 μL of 10 × diluted cDNA), and 10 μL SYBR Green PCR master mix (Applied Biosystems). Amplification was conducted in an Applied Biosystems Step One Plus real-time PCR machine. The level of mouse β-actin mRNA was used for normalization. Relative expression of mRNA was expressed as the fold change in comparison with the sham tissues. The primers used for quantitative real-time PCR are as follows:
Measurement of myeloperoxidase activity
Lung tissue samples were homogenized in potassium phosphate (KPO 4 ) buffer containing 0.5% hexadecyltrimethylammonium bromide. After centrifugation, the supernatant was diluted in a reaction solution, and the rate of change in optimal density for 30 seconds was measured at 460 mm to calculate myeloperoxidase (MPO) activity.
Statistical analysis
Data are expressed as the mean ± standard error of the mean and compared by one-way analysis of variance and the StudentNewman-Keuls test for multiple group comparisons. A t -test was used for comparison of CIRP serum levels between sham and vehicle mice. Significance was considered at P < .05 between the experimental groups. Our group size (n = 5 per group) was comparable to that in our previous work with intestinal I/R and ultimately were justified by statistical significance.
Results
CIRP is increased in serum after intestinal I/R
We first found that the levels of CIRP in serum were significantly elevated in mice 4 hours after intestinal I/R in the vehicle-treated mice (266 ± 101.4 pg/mL), as compared with shamoperated mice in which levels were not detectable ( P < .05) ( Fig  1 ) . This result ensures that our intestinal I/R model created enough damage to produce extracellular CIRP and, thus, is an appropriate model for testing whether C23 could antagonize CIRP. We did not include CIRP levels in C23-treated mice as C23 is protective against inflammation and would interrupt the positive feedback loop that increases CIRP level. Thus, the C23-treated mice may have a diminished CIRP level that is not indicative of severity of intestinal I/R in those mice.
Levels of serum and intestinal TNF-α are attenuated in C23-treated mice
We next measured the levels of proinflammatory cytokine TNF-α in both serum and intestinal tissue lysate for our experimental groups. The level of TNF-α in serum was significantly elevated by 25-fold in the vehicle group as compared with the sham group (12.4 ± 5.0 pg/mL vs 316 ± 76.9 pg/mL, P < .05). The C23 group experienced a 71% decrease in serum TNF-α as compared with the vehicle-treated mice (316 ± 76.9 pg/mL vs 89.3 ± 10.8 pg/mL, P < .05) ( Fig 2 , A ) . Likewise, in the intestine the level of TNF-α in the vehicle group was elevated 3-fold compared with that in the sham group (75.3 ± 9.4 pg/mg vs 220 ± 29.0 pg/mg, P < .05). We observed a significant 69% decrease in the TNF-α level in the intestine from the C23 treatment group as compared with that of the vehicle-treated mice (220 ± 29.0 pg/mg vs 68.3 ± 11.8 pg/mg, P < .05) ( Fig. 2 , B ) .
C23 treatment mitigates organ injury after intestinal I/R
We next sought to detect differences in organ injury between our experimental groups using the surrogates AST and LDH in serum. Levels of AST ( Fig 3 , A ) and LDH ( Fig 3 , B ) in the serum of vehicle mice (312 ± 85.1 and 939 ± 175.0 IU/L, respectively) were elevated 5-fold and 76-fold, respectively, when compared with those of the sham group (54 ± 3.6 and 12 ± 1.5 IU/L, respectively). In contrast, the C23 treatment group observed a 53% reduction in AST (147 ± 10.7 IU/L) and a 48% reduction in LDH (488 ± 102.0 IU/L) relative to the vehicle group ( P < .05).
C23 reduces intestinal tissue damage and myeloid/granulocyte infiltration in intestine from intestinal I/R
To ascertain the effect of C23 on intestinal tissue after I/R, we examined and scored randomized hematoxylin and eosin-stained sections of intestine from our experimental groups. In Fig 4 , A , the intestinal tissue sections of the vehicle group manifested severe villus blunting and transmural myonecrosis as compared with the C23-treated intestinal tissue sections, which manifested less villus blunting and no transmural necrosis. The vehicle-treated group had an average intestinal injury score of 2.5 ± 0.09 out of a maximum score of 4, a 10-fold increase in damage as compared with sham mice (0.26 ± 0.05) ( P < .05). The intestinal sections from the C23-treated mice, with an average score of 1.3 ± 0.08, exhibited a 48% reduction in histology injury score as compared with the vehicletreated mice ( P < .05) ( Fig 4 , B ) . The innate immune cells that are most often responsible for the inflammatory damage after I/R are neutrophils and macrophages. To demonstrate the infiltration of these cells in our intestinal I/R model, we stained the intestinal sections using anti-Ly6G/C an- tibodies for each of our experimental groups ( Fig 4 , C ) . We observed a significant increase in the numbers of Ly6G/C positive cells in the vehicle-treated sections (68 ± 6.8 cells/hpf) as compared with the sham-treated sections (10 ± 0.9 cells/hpf) ( Fig 4 ,  D ) . Furthermore, we observed a significant decrease in the number of Ly6G/C-stained cells in the intestinal sections of C23-treated mice (28 ± 2.8 cells/hpf) as compared with those from the vehicletreated group ( P < .05).
Lung IL-6 gene expression is attenuated in C23-treated mice in intestinal I/R
To determine the remote effects of CIRP-induced inflammation in mice undergoing intestinal I/R, we measured gene expression of IL-6 in lung tissue lysate from our 3 experimental groups. Expression of IL-6 at the mRNA level was increased by 36-fold in the vehicle-treated group as compared with sham-treated mice ( Fig 5 ) . IL-6 expression in the C23-treated animals diminished significantly by 85% in comparison to that in the vehicle-treated group ( P < .05) ( Fig 5 ) .
Decreased levels of MIP-2 and MPO in lungs of C23-treated mice following intestinal I/R
We finally examined the remote lung tissue for signs of activity of a key immune cell involved in I/R injury, the neutrophil. We used gene expression of the neutrophil chemokine MIP-2 and the level of MPO activity as surrogates for the presence of neutrophils. MIP-2 gene expression was elevated 163-fold in the vehicle-treated group as compared with the sham-operated group ( P < .05) ( Fig 6 ,  A ) . MIP-2 expression in C23-treated mice (15-fold greater than that of the sham group) exhibited a 91% decrease compared with the vehicle-treated mice ( P < .05). Similarly, MPO activity was increased 13-fold in the vehicle group as compared with the sham mice ( Fig. 6 , B ) . MPO activity in the C23-treated mice (10-fold above sham) was reduced significantly by 25% as compared with the vehicle-treated mice ( P < .05) ( Fig. 6 , B ) .
Discussion
We found that after intestinal I/R, serum levels of CIRP were significantly induced in mice. Our previous study found that the deficiency of CIRP in CIRP -/-mice protected animals from intestinal I/R injuries. 20 Here, we implemented a reliable, safe, and clinically relevant approach to antagonize CIRP with C23 and evaluated the beneficial outcomes in intestinal I/R injuries. Our data clearly indicate inhibition of the serum levels of the proinflammatory cytokine TNF-α and inflammation and injury parameters in local (intestine) and remote organ (lung) after C23 treatment in intestinal I/R injury model in mice.
In the present intestinal I/R injury model, we did not notice a significant increase in TNF-α levels in lung tissues 4 hours after intestinal I/R injury. As such, treatment with C23 also did not cause noticeable inhibition of TNF-α levels in lung after intestinal I/R injuries. The severity of intestinal I/R injury and the timing of sample collection after intestinal I/R in mice might play an important role in optimal TNF-α production in lungs. In line with this finding, Soares et al reported that TNF-α is not associated with intestinal I/R-induced lung inflammation. 23 They found that after intestinal I/R injury in mice, several cytokines are upregulated in lungs, in particular IL-6, but not TNF-α. Furthermore, neutralization of TNF-α by antibodies did not affect neutrophil recruitment to the lungs, the cytokine response, and pulmonary injury. The inflammatory response in the lungs in the absence of TNF-α or of TNF receptors was not significantly different from that of WT controls on intestinal I/R injury. 23 That study did, however, indicate that TNF-α is elevated in intestinal tissue after intestinal I/R and appears to be responsible in part for intestinal inflammation. The importance of IL-6 in lung inflammation seen after intestinal I/R was described further by Yuan et al . 24 They revealed that IL-6 knockdown ameliorates ALI induced by intestinal I/R in rats, indicating that IL-6 is a significant driver of lung inflammation in intestinal I/R. 24 It is for these reasons that we focused on the measurement of and difference in IL-6 in the lung tissue as a marker for inflammatory activation in the lung tissues instead of TNF-α, which was used as a marker for inflammation in the intestinal tissue.
After the initial activation of the innate immune response, adhesion of innate immune cells to endothelial cells within the intestine and the subsequent infiltration of these leukocytes into intestinal tissue represent the next step toward local damage during the maladaptive response of reperfusion. Leukocyte-vessel wall adhesion and plugging of microcirculation with leukocytes is an established mechanism of intestinal I/R damage. 10, 25 Riaz et al 26 revealed that by blocking neutrophil adhesion with anti-P-selectin antibody, neutrophil rolling and adhesion were reduced, which led to significantly less intestinal injury following intestinal I/R. Once innate cells enter intestinal parenchyma, they cause further damage through release of cytotoxic molecules, such as elastase and reactive oxygen species. Macrophages have been previously reported to express TNF-α when exposed in vitro to CIRP. 14 Thus, once these cells enter previously ischemic intestinal tissue, we hypothesize that macrophages produce further inflammation in part through CIRP stimulation. Ly6G and Ly6C were applied to our intestinal sections to stain neutrophils and macrophages, respectively, to measure adhesion and infiltration of these cells into the intestinal parenchyma. C23 significantly reduced the presence of these damaging innate immune cells. We applied an established intestinal injury scoring system to our hematoxylin and eosinstained intestinal sections to demonstrate the therapeutic effect of C23 treatment on amelioration of intestinal tissue injury. 22 Ultimately, by reducing the activation, adhesion, and infiltration of innate immune cells, C23 treatment significantly reduced the histologically evident damage as compared with the vehicle-treated mice.
Intestinal I/R causes not only local tissue inflammation but also a robust systemic inflammatory response. 27 In our study we used serum TNF-α levels to reveal a significant elevation in systemic inflammation compared with sham-treated mice. This elevation was accompanied by an elevation in AST and LDH, circulating markers of general cellular injury present in higher quantity in vehicletreated mice relative to sham-treated mice. C23 treatment significantly reduced levels of TNF-α, as well as those of AST and LDH, relative to vehicle-treated mice, indicating the ability of C23 to reduce systemic inflammation and injury in intestinal I/R. Following intestinal I/R we noticed a significant decrease in the tissue level of MPO activity and MIP-2 gene expression in C23-treated mice, although no significant difference in histologically evident damage was seen after 4 hours of reperfusion between vehicle-and C23-treated mice (data not shown). The discrepancy can be explained by the timing of the lung collection. We believe that we would likely see a difference at a later collection point (20 hours). Cen et al 16 reported a significant difference in the injury score between WT and CIRP -/-mice 20 hours after intestinal I/R injuries, whereas at 4 hours, lung injury scores did not significantly differ between CIRP -/-mice and WT mice undergoing intestinal I/R injury. Based on our previous experiences we believe the differences in lung damage require more than 4 hours to be evident histologically.
C23 is a 15-amino-acid peptide derived from human CIRP protein. 14 It has a strong affinity for binding to TLR4/MD2 complexes, the receptor for CIRP, as defined by surface plasmon resonance. 14 Although we have not directly illustrated that C23 functions by binding to and antagonizing MD2-TLR4 under in vivo conditions, our study did demonstrate C23's efficacy in inhibiting CIRP-induced proinflammatory responses in intestinal I/R injuries, possibly by interfering with the binding of CIRP to its receptor. Because C23 has been found to neutralize only CIRP's binding to TLR4 while allowing other TLR4 ligands to bind, this specificity may be more advantageous than general TLR4 inhibition, as TLR4 is heavily relied on for recognition and neutralization of bacterial pathogens. Furthermore, DAMP inhibition using a peptide confers a shorter drug half-life, less immunogenicity, and less expense than inhibition with an antibody. Finally, CIRP inhibition or genetic knockout in mice has not caused obvious side effects or increased mortality. In our previous study, we reported that the treatment of cells with C23 alone did not cause any toxicity or inflammatory or immunogenic activity, indicating C23 treatment has no apparent side effects or toxicity when delivered in vivo. 21 We previously reported extracellular CIRP's function as a DAMP in propagating inflammation and tissue damage in intestinal I/R through the use of CIRP knockout mice, which, while scientifically enlightening, is not translatable into a human treatment. This article describes the study of the novel peptide C23 and the potential for its translation into a therapy for human patients experiencing intestinal I/R injury. The clinical relevance of our intestinal I/R model is most directly applicable to a surgical scenario in which the patient has a return of perfusion with concomitant C23 treatment 60 minutes after the ischemic insult, such as a patient with vaso-occlusive disease that is recognized and treated early or a patient undergoing an elective procedure where there is a risk of intestinal I/R, such as intestinal transplantation and use of cardiopulmonary bypass during cardiac surgery or abdominal aortic clamping during vascular surgeries. Our model does not adequately represent the situation in which most vaso-occlusive patients find themselves; most vaso-occlusive patients have delayed presentation and treatment beyond 1 hour, leading to a prolonged ischemic time. Future study of C23's benefit will include intestinal I/R models with a delay before C23 treatment is administered. Still, we have found that the C23 peptide lowers intestinal inflammation and damage, as well as systemic and remote organ inflammation, after 60 minutes of ischemia. We thus recommend further study of this novel therapy.
